5817-96-9: 5,7-dihydro-6H-pyrrolo [2,3-d] pyrimidin-6-one impurity
It is one of impurity present in Tofacitinib, Tofacitinib is an inhibitor of Janus kinases is a group of intracellular enzymes involved in signaling pathways that affect hematopoiesis and immune cell function, prevent the body from responding to cytokine signals. Tofacitinib is a partial and reversible Janus kinase inhibitor that prevents the body from responding to cytokine signals. which use is associated with a rapid decrease in C-reactive protein dose-dependent decreases in natural killer cells, and dose-dependent increases in B cells.
Additional information on CAS 5817-96-9
5, 7-dihydro-6H-pyrrolo [2, 3-d] pyrimidin-6-one
Cada, D. J., Demaris, K., Levien, T. L., & Baker, D. E. (2013). Tofacitinib. Hospital Pharmacy, 48(5), 413–424. https://doi.org/10.1310/hpj4805-413
Other products related to tofacitinib
|CAS No.||Name of Impurity||Parent Drug||Catalogue No.|